Latest Breaking News On - Leap healthcare collaborative - Page 1 : comparemela.com

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R

United statesSan franciscoEric van zantenUniversity of californiaAtossa therapeutics incSelective estrogen receptor modulatorRe evaluating conditionsActive surveillance suitabilityDuctal carcinoma in situCarcinoma in situSteven quayChief executiveQuantum leap healthcare collaborativeSilicon valleyLeap healthcare collaborativeBreast cancer

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innov.

San franciscoUnited statesEric van zantenUniversity of californiaCancer biomarkers consortiumFoundation for the national institutes of healthDrug administrationAtossa therapeutics incSelective estrogen receptor modulatorSteven quayChief executiveQuantum leap healthcare collaborativeNational institutesCancer biomarkersOptimization pilot protocolLeap healthcare collaborative

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoLaura essermanStemline elacestrantStemline therapeutics incUniversity of californiaNational cancer instituteMenarini groupUs food drug administrationLeap healthcare collaborativeRe evaluating conditionsActive surveillance suitabilityDuctal carcinoma in situAtossa therapeuticsHavah therapeuticsStemline therapeutics

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm

SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need

United statesUniversity of california san franciscoSan franciscoEric van zantenLaura essermanJacqueline murrayExchange commissionDrug administrationFoundation for the national institutes of healthUniversity of californiaCancer biomarkers consortiumAtossa therapeutics incQuantum leap healthcare collaborativeSelective estrogen receptor modulatorNational institutesCancer biomarkers

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoJohn houstonLaura essermanPfizer incPrnewswire arvinas incExchange commissionDrug administrationUniversity of californiaQuantum leap healthcare collaborativeOptimization platformQuantum leapDiscovery engineLeap healthcare collaborativePredict your therapeutic responseImaging and